DNA amplifications in breast cancer are frequent on chromosome 11q, in which multiple driver oncogenes likely reside in addition to cyclin D1 (CCND1). One such candidate, the scaffolding adapter protein, GRB2-associated binding protein 2 (GAB2), functions in ErbB signaling and was recently shown to enhance mammary epithelial cell proliferation, and metastasis of ERBB2 (HER2/neu)-driven murine breast cancer. However, the amplification status and function of GAB2 in the context of amplification remain undefined. In this study, by genomic profiling of 172 breast tumors, and fluorescence in situ hybridization validation in an independent set of 210 scorable cases, we observed focal amplification spanning GAB2 (11q14.1) independent of CCND1 (11q13.2) amplification, consistent with a driver role. Further, small interfering RNA (siRNA)-mediated knockdown of GAB2 in breast cancer lines (SUM52, SUM44PE and MDA468) with GAB2 amplification revealed a dependency on GAB2 for cell proliferation, cell-cycle progression, survival and invasion, likely mediated through altered phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling. GAB2 knockdown also reduced proliferation and survival in a cell line (BT474) with ERBB2 amplification, consistent with the possibility that GAB2 can function downstream of ERBB2. Our studies implicate focal amplification of GAB2 in breast carcinogenesis, and underscore an oncogenic role of scaffolding adapter proteins, and a potential new point of therapeutic intervention.
DNA amplifications in breast cancer are frequent on chromosome 11q, in which multiple driver oncogenes likely reside in addition to cyclin D1 (CCND1). One such candidate, the scaffolding adapter protein, GRB2-associated binding protein 2 (GAB2), functions in ErbB signaling and was recently shown to enhance mammary epithelial cell proliferation, and metastasis of ERBB2 (HER2/neu)-driven murine breast cancer. However, the amplification status and function of GAB2 in the context of amplification remain undefined. In this study, by genomic profiling of 172 breast tumors, and fluorescence in situ hybridization validation in an independent set of 210 scorable cases, we observed focal amplification spanning GAB2 (11q14.1) independent of CCND1 (11q13.2) amplification, consistent with a driver role. Further, small interfering RNA (siRNA)-mediated knockdown of GAB2 in breast cancer lines (SUM52, SUM44PE and MDA468) with GAB2 amplification revealed a dependency on GAB2 for cell proliferation, cell-cycle progression, survival and invasion, likely mediated through altered phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling. GAB2 knockdown also reduced proliferation and survival in a cell line (BT474) with ERBB2 amplification, consistent with the possibility that GAB2 can function downstream of ERBB2. Our studies implicate focal amplification of GAB2 in breast carcinogenesis, and underscore an oncogenic role of scaffolding adapter proteins, and a potential new point of therapeutic intervention.
Oncogene ( Keywords: GAB2; DNA amplification; genomic profiling; array-based comparative genomic hybridization; breast cancer; oncogene dependency Breast cancer is the second leading cause of cancer death in women in the United States (Jemal et al., 2007) , affecting all races and ethnicities. Breast cancer develops through multiple genetic alterations, including amplification and resultant overexpression of oncogenes. The discovery and characterization of amplified oncogenes informs the understanding of breast cancer pathogenesis, and provides useful biomarkers and therapeutic targets. This is best exemplified by ERBB2 (Her2/neu; 17q12), a receptor tyrosine kinase amplified in 20-30% of breast cancers and the target of molecularly directed therapies, such as trastuzumab (Pegram et al., 2000) .
The chromosomal region 11q13-q14 is amplified in 15-20% of breast cancers, and the finding of distinct loci amplified independently or in combination suggests the presence of multiple 'driver' oncogenes (Karlseder et al., 1994; Ormandy et al., 2003) . Within the proximal (that is, more centromeric) region, cyclin D1 (CCND1; at 11q13.2) has been considered the main driver, promoting G1-to S-phase cell-cycle progression. Other candidate oncogenes frequently co-amplified at 11q13.2 include fibroblast growth factor-3 (also called int-2) and cortactin (EMSI) (Karlseder et al., 1994) . More distally, EMSY (at 11q13.5), encoding a binding partner of breast cancer 2, early onset (BRCA2), has been nominated as an amplicon driver (Hughes-Davies et al., 2003) . A higher-resolution map of 11q amplification should more clearly pinpoint relevant breast cancer genes.
To delineate amplification on 11q (and elsewhere) at high resolution, we profiled 172 primary breast cancers by array-based comparative genomic hybridization, using a complementary DNA (cDNA) microarray platform with an average mapping resolution (interprobe distance) of B70 Kb. Amplicon structure was complex (Figure 1a) , with a major proximal amplicon at 11q13.2-q13.3, spanning CCND1, in 28% (48/172) of breast cancer cases. Another prominent amplicon was found distally at 11q13.5-q14.1 in 15% (25/172) of cases. Notably, the distal amplicon occurred without coamplification at 11q13.2 (CCND1) in 3% (5/172) of cases, suggesting it harbored a distinct driver oncogene. Distal amplification was not significantly associated with estrogen receptor status or ERBB2 amplification, but occurred more frequently among non-ERBB2-associated gene-expression subtypes (that is, luminal A/B, basal-and normal-like subtypes) (Sorlie et al., 2001 ) (P ¼ 0.017; Fisher's exact test).
To validate the array-based comparative genomic hybridization findings, we performed fluorescence in situ hybridization (Figure 1b ) on tissue microarrays, comprising an independent cohort of 495 breast cancer cases with a median clinical follow-up of 14 years. Consistent with our comparative genomic hybridization findings, the distal amplicon (11q14.1) was present in 8% (16/210) of scorable cases, and occurred without co-amplification at 11q13.2 (CCND1) in 4 of 14 cases that were scorable at both loci. Distal (11q14.1) amplification was not significantly associated with any clinicopathological variables, including tumor size, grade, node status, HER2 and overall survival, with the exception of a trend toward positive association with estrogen receptor positivity (P ¼ 0.094, chi-square test).
The smallest common region of distal amplification was telomeric to EMSY, and spanned just four genes (ALG8, KCTD21, USP35 and GAB2) within 11q14.1 Tumors (this study)
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Figure 1 GAB2 amplification in breast cancer M Bocanegra et al ( Figure 1a ), of which GAB2 was a particularly intriguing oncogene candidate. GRB2-associated binding protein 2 (GAB2) is a scaffolding adapter protein that amplifies signaling from cytoplasmic and receptor tyrosine kinases by recruiting (with GRB2) signaling molecules such as SHP2 and the p85 subunit of phosphatidylinositol 3-kinase (PI3K) (Gu and Neel, 2003; Sarmay et al., 2006) . GAB2 has been shown to be required for v-SEA and BCR/ABL-mediated transformation (Sattler et al., 2002; Ischenko et al., 2003) . Although mainly studied in immune cells, GAB2 was recently found overexpressed in a subset of breast cancer cell lines (mainly estrogen receptor positive), in which it was phosphorylated in response to growth factor-receptor tyrosine kinase (including ErbB family) stimulation, and induced by estrogens (Daly et al., 2002) . Engineered overexpression of GAB2 in MCF10A breast epithelial cells was shown to enhance cell proliferation in a three-dimensional culture (Bentires-Alj et al., 2006; Brummer et al., 2006) , and knockout of GAB2 suppressed metastasis in an ERBB2-driven mouse model of breast cancer (mouse mammary tumor virus-neu) (Ke et al., 2007) . Although such studies support a role of GAB2 in breast tumorigenesis, the functional significance of GAB2 when amplified remains unexplored. Consistent with an oncogenic function, we found GAB2 transcript levels (by microarray) increased when amplified in our set of 172 breast cancers (although not reaching significance in this study), in a publicly available data set of 101 breast cancers (Chin et al., 2006) (P ¼ 0.001), and in a separately profiled set of 52 breast cancer cell lines (Kao et al., 2009 ) (P ¼ 0.002) (Figure 1c ). Amplification-driven overexpression of GAB2 at the protein level was confirmed using western blot (Figure 1d ) that surveyed select breast cancer cell lines with or without GAB2 amplification (Figure 1a , right-hand side).
To address a functional significance of amplificationdriven GAB2 overexpression, we used RNA interference to knockdown the expression of GAB2 in three breast cancer cell lines (SUM52, SUM44PE and MDA-MB-468) with 11q14.1 (GAB2) gain/amplification. Transfection of a small interfering RNA (siRNA) pool, comprising two siRNAs targeting distinct sequences of GAB2, resulted in efficient GAB2 knockdown (X75%) in the three cell lines (Figure 2a ). GAB2 knockdown in these lines led to significantly reduced cell proliferation (measured by a mitochondrial activity assay) when compared with a non-targeting control siRNA pool (Figure 2b) . Transfection of the GAB2 siRNAs individually led to similarly decreased GAB2 levels and cell proliferation (not shown), whereas no such effect was observed for the GAB2 siRNA pool in breast cancer cell lines (HCC2688 and BT20) without GAB2 amplification/overexpression (Figure 2b ), supporting the specificity of siRNA targeting. The effect of GAB2 knockdown on cell proliferation was attributable to both decreased cell-cycle progression (evidenced by reduced S phase; Figure 2c ) and increased apoptosis (Figure 2d ). GAB2 knockdown also led to decreased cell invasion (Figure 2e ).
Our findings support the amplification-driven overexpression of GAB2 contributing to diverse oncogenic phenotypes in breast cancer. Signaling through GAB2 has been shown to activate both mitogen-activated protein kinase (MAPK) and PI3K pathways (with relevance to cell proliferation, survival and invasion), although the relative contribution of each pathway in breast cancer remains uncertain (Bentires-Alj et al., 2006; Brummer et al., 2006) . To determine the relevant downstream pathways in GAB2-amplified lines, we measured phospho-levels of MAPK (p44/42) and AKT as readouts of respective MAPK and PI3K pathway activation. RNA interference-mediated knockdown of GAB2 led to decreased phospho-AKT levels in all three GAB2-amplified cell lines (SUM52, SUM44 and MDA468), and to decreased p-MAPK levels (with or without decreased total MAPK) in SUM44 and to a Figure 1 Focal amplification at 11q14.1 spans GRB2-associated binding protein 2 (GAB2). (a) Genomic profiles using comparative genomic hybridization (CGH) on complementary DNA (cDNA) microarrays for 172 primary breast tumors, and six selected breast cancer cell lines, shown for a segment of chromosome 11q13.2-q14.1. Genes (rows) are ordered by chromosome position. Red and blue intensities (log 2 scale shown) indicate gains and losses, respectively, called using cghFLasso (Tibshirani and Wang, 2008) . Selected genes are indicated (those not represented on the array are denoted by gray text). Key samples (columns) delineating the 11q14.1 amplicon core (bracketed by dashed yellow lines, lower) are identified by asterisks below. Breast tumors represent three Norwegian (Doxo, Fumi and Ull) and one Korean cohort, and were used with patient consent and the approval of the institutional review board. CGH was performed on cDNA microarrays from the Stanford Functional Genomics Facility containing 39 632 human cDNAs (representing 22 488 different mapped human genes/cDNAs), using our published protocol (Pollack et al., 2002) . A preliminary description of the cohorts and CGH profiles was recently published (Bergamaschi et al., 2008; Kao et al., 2009) , and the complete microarray data set is accessible from the Gene Expression Omnibus repository (GSE12827). (b) Fluorescence in situ hybridization (FISH) assessment of GAB2 amplification in an independent breast cancer cohort. Shown are representative GAB2-amplified and nonamplified cases. Locus-specific bacterial artificial chromosomes (BACs) (CTD-254A24, RP11-452H21) spanning 350 Kb at 11q14.1 (GAB2) were labeled with SpectrumOrange, and co-hybridized with a SpectrumGreen (shown here, or Aqua)-labeled centromere probe (CEP11; Vysis, Abbott Park, IL, USA). Scoring was performed using FISH on tissue arrays comprising a cohort of 210 scorable breast cancer cases archived from the Vancouver General Hospital (Bergamaschi et al., 2008 ). An 11q14.1/CEP11 ratio X2 was scored as amplification. (c) Relative GAB2 transcript levels, measured using microarray, in breast cancers (Chin et al., 2006; Bergamaschi et al., 2008) and breast cancer cell lines (Kao et al., 2009) . Box plots show 25th, 50th (median) and 75th expression quartiles for amplified vesus non-amplified samples (sample number, n, shown); P-values (Mann-Whitney U-test) are indicated. (d) GAB2 protein levels using western blot in selected breast cancer cell lines with GAB2 gain ( þ ) or high-level amplification ( þ þ ). Cell lines were obtained from America Type Culture Collection (ATCC) and Asterand, and cultured as recommended. GAB2 antibody (Cell Signaling Technology, Danvers, MA, USA) was used at 1:1000 dilution. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) serves as a loading control.
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M Bocanegra et al lesser extent in MDA468 (with phospho-MAPK not readily detected in SUM52; Figure 3 ). These findings suggest that GAB2 (when amplified) likely signals mainly through the PI3K pathway, but that the relative contribution of PI3K and MAPK pathways may be cell context dependent. GAB2 amplifies signaling from receptor tyrosine kinases, and previous studies have implicated GAB2 in mediating ERBB2 oncogenesis, in which GAB2 knockdown suppresses ERBB2-driven murine tumor development (Bentires-Alj et al., 2006) and metastasis (Ke et al., 2007) . To clarify the role of GAB2 in ERBB2 signal transduction, we used RNA interference to knockdown GAB2 in a breast cancer cell line (BT474) with ERBB2 but not GAB2 amplification (although with detectable GAB2 expression; Figure 1d ). siRNA-mediated Figure 2 GRB2-associated binding protein 2 (GAB2) amplification drives cell proliferation, survival and invasion. (a) Confirmation of small interfering RNA (siRNA)-mediated knockdown of target protein GAB2 using western blot. ON-TARGETplus siRNAs targeting GAB2 (5 0 -GATGCAGGCCTGACCTTTA-3 0 and 5 0 -GCACCGGCAGCGTTGATTA-3 0 ), along with an ON-TARGETplus siCONTROL Non targeting Pool, were obtained from Dharmacon (Lafayette, CO, USA). A total of 1.5-3 Â 10 5 cells were transfected with 50 nmol siRNA using RNAiMax (Invitrogen, Carlsbad, CA, USA), and cell lysates were prepared 72 h after transfection. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) serves as a loading control. (b) Cell proliferation (using mitochondrial activity as a surrogate), quantified using WST-1 assay (Roche, Indianapolis, IN, USA), 1, 3 and 5 days after transfection. (c) Cell-cycle distribution quantified 3 days after transfection by 5-bromodeoxyuridine (BrdU) incorporation (BrdU-FITC Flow kit; BD Biosciences, San Jose, CA, USA). Fraction of cells in G1, S and G2/M is indicated. (d) Apoptosis quantified 5 days after transfection using annexin-V staining (Vybrant Apoptosis Assay kit; Invitrogen). (e) Invasion quantified using matrigel Boyden chamber assay (BD Biosciences); at 24 h after re-plating transfected cells in a 0.5%/5% serum gradient, cells were stained with crystal violet and cells traversing the membrane counted. All assays were performed as triplicate transfections. *Po0.05; **Po0.01 (Student's t-test; GAB2-siRNA compared with control).
GAB2 amplification in breast cancer M Bocanegra et al knockdown of GAB2 (Figure 4a ) resulted in decreased cell proliferation, less so than with ERBB2 knockdown (which also reduced GAB2 levels) (Figures 4a and b ), but consistent with the possibility that GAB2 can function downstream of ERBB2. The effect of GAB2 knockdown on cell proliferation was attributable mainly to increased apoptosis, rather than altered cell-cycle progression (Figures 4c and d) , and seemed to be mediated through altered PI3K signaling (that is, decreased phospho-AKT levels; Figure 4a ). Our findings are consistent with GAB2 linking ERBB2 (when amplified) to downstream signaling pathways, although other scaffolding adapters (for example, GAB1) might also have a role.
In this study, we report that GAB2 is focally amplified, and that GAB2 amplification drives cell proliferation, survival and invasion. Although previous studies have conflicted, assigning a primary role of GAB2 to either cell proliferation (Bentires-Alj et al., 2006) or to invasion/metastasis (Ke et al., 2007) , our findings support, in the relevant context of GAB2 amplification, an important contribution to both phenotypes. Our results are also consistent with a downstream role of GAB2 in ERBB2 signaling, suggesting, although speculative, a possible role of GAB2 amplification/overexpression in resistance to ERBB2-targeted therapy.
Although previously noted to be amplified (Bentires-Alj et al., 2006) , our studies are the first to locate GAB2 within a focal amplicon, recurring and independent of CCND1 amplification, supporting its role as a primary driver oncogene. Although we cannot exclude the possibility that genes (ALG8, KCTD21 and USP35) co-amplified with GAB2 are relevant, we note that their functions have no obvious connection with oncogenesis. By knocking down GAB2 in breast cancer cell lines with GAB2 amplification, we have also shown the contribution (and dependency) of amplificationdriven GAB2 overexpression in cell proliferation, survival and invasion. Our findings highlight a novel role of scaffolding adapter proteins as primary genetic drivers of tumorigenesis. Further, the finding of oncogene dependency underscores the potential utility of scaffolding adapters as targets for new moleculardirected therapies.
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